TAK-861 Shows Promise in Phase 2b Narcolepsy Type 1 Trial | Sleep Review
TAK-861 demonstrated significant and sustained improvements in the treatment of narcolepsy type 1 in a phase 2b clinical trial.| Sleep Review
TAK-861 demonstrated significant and sustained improvements in the treatment of narcolepsy type 1 in a phase 2b clinical trial.| Sleep Review
Drug candidates aim to address the root cause of narcolepsy type 1—orexin deficiency—with some also being explored for NT2 and IH.| Sleep Review
As the first orexin-2 receptor agonist nears FDA approval, preclinical compound BP1.15205 shows promise for its higher potency.| Sleep Review
